Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC.MIRA · Entity 7362 | Director · Chief Executive Officer | March 30, 2026 | April 01, 2026 |
| Telomir Pharmaceuticals, Inc.TELO · Entity 6962 | Director · CEO and Chairman | May 21, 2026 | May 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MIRA PHARMACEUTICALS, INC.
Report date March 30, 2026 · Filed April 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2036-03-30 | Direct | 83,500 |
Reported balance
After 2026-03-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-30 · Grant · Acquired 83,500 · Balance 83,500 F1: Each restricted stock unit represents a right to receive one share of Issuer's common stock. F2: The RSUs were issued to the Reporting Person on the Grant Date, pursuant to the Plan. All of the RSU shall vested on the Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a right to receive one share of Issuer's common stock.
F2: The RSUs were issued to the Reporting Person on the Grant Date, pursuant to the Plan. All of the RSU shall vested on the Grant Date.
Telomir Pharmaceuticals, Inc.
Report date May 21, 2026 · Filed May 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Incentive Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.30 · Expires 2036-05-21 | Direct | 1,960,170 |
Reported balance
After 2026-05-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-21 · Grant · Acquired 1,960,170 · Balance 1,960,170 F2: The reporting person agreed to cancellation of options granted to him on 08/27/2024 and 05/27/2025, in exchange for new options having a lower exercise price. F1: The options are fully exercisable. |
| Incentive Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.02 · Expires 2034-08-27 | Direct | 0 |
Reported balance
After 2026-05-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-21 · Disposition to issuer · Disposed 1,960,170 · Balance 0 F2: The reporting person agreed to cancellation of options granted to him on 08/27/2024 and 05/27/2025, in exchange for new options having a lower exercise price. |
| Non-Qualified Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.30 · Expires 2036-05-21 | Direct | 2,000,000 |
Reported balance
After 2026-05-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-21 · Grant · Acquired 2,000,000 · Balance 2,000,000 F2: The reporting person agreed to cancellation of options granted to him on 08/27/2024 and 05/27/2025, in exchange for new options having a lower exercise price. F1: The options are fully exercisable. |
| Non-Qualified Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.10 · Expires 2035-05-27 | Direct | 0 |
Reported balance
After 2026-05-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-21 · Disposition to issuer · Disposed 2,000,000 · Balance 0 F2: The reporting person agreed to cancellation of options granted to him on 08/27/2024 and 05/27/2025, in exchange for new options having a lower exercise price. |
| Common StockSEC Table I · non-derivative | Direct | 7,319,710 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 7,319,710 |
Filing footnotes · ownership attribution and instrument terms
F1: The options are fully exercisable.
F2: The reporting person agreed to cancellation of options granted to him on 08/27/2024 and 05/27/2025, in exchange for new options having a lower exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 23, 2026 00:00 UTC | Telomir Pharmaceuticals, Inc. TELO · Entity 6962 | Disposition to issuerNon-Qualified Stock Options (right to buy) · Derivative | 2,000,000 | Not disclosed Strike: $2.10 | Not disclosed |
DisclosureSEC source: 0001493152-26-025116 · ownership.xml · derivative · entry 5 Aminov Erez · CIK 0001986112 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000,000 shares Expires 2035-05-27 F2 · price: The reporting person agreed to cancellation of options granted to him on 08/27/2024 and 05/27/2025, in exchange for new options having a lower exercise price. Read SEC document |
| May 21, 2026 Filed May 23, 2026 00:00 UTC | Telomir Pharmaceuticals, Inc. TELO · Entity 6962 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 2,000,000 | Not disclosed Strike: $1.30 | Not disclosed |
DisclosureSEC source: 0001493152-26-025116 · ownership.xml · derivative · entry 4 Aminov Erez · CIK 0001986112 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2036-05-21 F2 · price: The reporting person agreed to cancellation of options granted to him on 08/27/2024 and 05/27/2025, in exchange for new options having a lower exercise price. F1 · derivative.exercise_date: The options are fully exercisable. F2 · balance_after: The reporting person agreed to cancellation of options granted to him on 08/27/2024 and 05/27/2025, in exchange for new options having a lower exercise price. Read SEC document |
| May 21, 2026 Filed May 23, 2026 00:00 UTC | Telomir Pharmaceuticals, Inc. TELO · Entity 6962 | Disposition to issuerIncentive Stock Options (right to buy) · Derivative | 1,960,170 | Not disclosed Strike: $5.02 | Not disclosed |
DisclosureSEC source: 0001493152-26-025116 · ownership.xml · derivative · entry 3 Aminov Erez · CIK 0001986112 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,960,170 shares Expires 2034-08-27 F2 · price: The reporting person agreed to cancellation of options granted to him on 08/27/2024 and 05/27/2025, in exchange for new options having a lower exercise price. Read SEC document |
| May 21, 2026 Filed May 23, 2026 00:00 UTC | Telomir Pharmaceuticals, Inc. TELO · Entity 6962 | GrantIncentive Stock Options (right to buy) · Derivative | 1,960,170 | Not disclosed Strike: $1.30 | Not disclosed |
DisclosureSEC source: 0001493152-26-025116 · ownership.xml · derivative · entry 2 Aminov Erez · CIK 0001986112 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,960,170 Underlying: Common Stock · 1,960,170 shares Expires 2036-05-21 F2 · price: The reporting person agreed to cancellation of options granted to him on 08/27/2024 and 05/27/2025, in exchange for new options having a lower exercise price. F1 · derivative.exercise_date: The options are fully exercisable. F2 · balance_after: The reporting person agreed to cancellation of options granted to him on 08/27/2024 and 05/27/2025, in exchange for new options having a lower exercise price. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 20:05 UTC | Telomir Pharmaceuticals, Inc. TELO · Entity 6962 | OtherCommon Stock | 7,319,710 | $1.37 | $10,028,002.70 |
DisclosureSEC source: 0001493152-26-018911 · ownership.xml · nonDerivative · entry 1 Aminov Erez · CIK 0001986112 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,319,710 F1 · security: The shares of common stock, no par value of the Issuer issued to the Reporting Person are in exchange for the Reporting Person's shares of TELI Pharmaceuticals, Inc. ("TELI") in connection with the Issuer's acquisition of TELI. F1 · kind: The shares of common stock, no par value of the Issuer issued to the Reporting Person are in exchange for the Reporting Person's shares of TELI Pharmaceuticals, Inc. ("TELI") in connection with the Issuer's acquisition of TELI. F1 · price: The shares of common stock, no par value of the Issuer issued to the Reporting Person are in exchange for the Reporting Person's shares of TELI Pharmaceuticals, Inc. ("TELI") in connection with the Issuer's acquisition of TELI. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 21:00 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantRestricted Stock Units · Derivative | 83,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-014697 · ownership.xml · derivative · entry 1 Aminov Erez · CIK 0001986112 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,500 Underlying: Common Stock · 83,500 shares Expires 2036-03-30 F1 · derivative.exercise_price: Each restricted stock unit represents a right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The RSUs were issued to the Reporting Person on the Grant Date, pursuant to the Plan. All of the RSU shall vested on the Grant Date. Read SEC document |
| December 17, 2025 Filed Feb 18, 2026 01:30 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantStock Options (right to buy) · Derivative | 3,155,170 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001493152-26-007226 · ownership.xml · derivative · entry 8 Aminov Erez · CIK 0001986112 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,155,170 Underlying: Common Stock · 3,155,170 shares Expires 2035-12-17 F1 · derivative.exercise_price: Represents the grant of Issuer's common stock, par value $0.0001 ("Common Stock") that should have been reported on Form 4. F5 · kind: Represents grants of options with underlying shares of Common Stock under the Plan, for awards granted in accordance with the Issuer's CEO's Long-Term Incentive Plan. The options hereunder vested upon issuance. F5 · shares: Represents grants of options with underlying shares of Common Stock under the Plan, for awards granted in accordance with the Issuer's CEO's Long-Term Incentive Plan. The options hereunder vested upon issuance. F5 · derivative.exercise_date: Represents grants of options with underlying shares of Common Stock under the Plan, for awards granted in accordance with the Issuer's CEO's Long-Term Incentive Plan. The options hereunder vested upon issuance. F5 · derivative.underlying_shares: Represents grants of options with underlying shares of Common Stock under the Plan, for awards granted in accordance with the Issuer's CEO's Long-Term Incentive Plan. The options hereunder vested upon issuance. Read SEC document |
| October 16, 2025 Filed Feb 18, 2026 01:30 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | Exercise / conversionStock Options (right to buy) · Derivative | 379,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001493152-26-007226 · ownership.xml · derivative · entry 7 Aminov Erez · CIK 0001986112 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 379,000 Underlying: Common Stock · 379,000 shares Expires 2034-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Represents exercise of 379,000 stock options to purchase Common Stock under the Plan that were issued to the Reporting Person on May 28, 2024 that were vested in full and became exercisable on the same date, pursuant to a grant under the Plan at an exercise price of $0.84 each. Read SEC document |
| October 16, 2025 Filed Feb 18, 2026 01:30 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | Exercise / conversionStock Options (right to buy) · Derivative | 234,595 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001493152-26-007226 · ownership.xml · derivative · entry 6 Aminov Erez · CIK 0001986112 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,595 Underlying: Common Stock · Not disclosed shares Expires 2034-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents exercise of 234,595 stock options to purchase Common Stock under the Plan that were issued to the Reporting Person on March 26, 2024, with 50% of such options vesting on the six-month anniversary date of the grant, and the remaining half vesting on the one-year anniversary date of the grant, pursuant to a grant under the Plan at an exercise price of $1.16 each. Read SEC document |
| October 16, 2025 Filed Feb 18, 2026 01:30 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | SaleCommon Stock | 613,595 | $2.11 | $1,294,685.45 |
DisclosureSEC source: 0001493152-26-007226 · ownership.xml · nonDerivative · entry 5 Aminov Erez · CIK 0001986112 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,592,666 F1 · kind: Represents the grant of Issuer's common stock, par value $0.0001 ("Common Stock") that should have been reported on Form 4. Read SEC document |
| October 16, 2025 Filed Feb 18, 2026 01:30 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | Exercise / conversionCommon Stock | 379,000 | $0.84 | $318,360.00 |
DisclosureSEC source: 0001493152-26-007226 · ownership.xml · nonDerivative · entry 4 Aminov Erez · CIK 0001986112 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,206,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the grant of Issuer's common stock, par value $0.0001 ("Common Stock") that should have been reported on Form 4. F4 · kind: Represents exercise of 379,000 stock options to purchase Common Stock under the Plan that were issued to the Reporting Person on May 28, 2024 that were vested in full and became exercisable on the same date, pursuant to a grant under the Plan at an exercise price of $0.84 each. F4 · price: Represents exercise of 379,000 stock options to purchase Common Stock under the Plan that were issued to the Reporting Person on May 28, 2024 that were vested in full and became exercisable on the same date, pursuant to a grant under the Plan at an exercise price of $0.84 each. Read SEC document |
| October 16, 2025 Filed Feb 18, 2026 01:30 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | Exercise / conversionCommon Stock | 234,595 | $1.16 | $272,130.20 |
DisclosureSEC source: 0001493152-26-007226 · ownership.xml · nonDerivative · entry 3 Aminov Erez · CIK 0001986112 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,827,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the grant of Issuer's common stock, par value $0.0001 ("Common Stock") that should have been reported on Form 4. F3 · kind: Represents exercise of 234,595 stock options to purchase Common Stock under the Plan that were issued to the Reporting Person on March 26, 2024, with 50% of such options vesting on the six-month anniversary date of the grant, and the remaining half vesting on the one-year anniversary date of the grant, pursuant to a grant under the Plan at an exercise price of $1.16 each. F3 · price: Represents exercise of 234,595 stock options to purchase Common Stock under the Plan that were issued to the Reporting Person on March 26, 2024, with 50% of such options vesting on the six-month anniversary date of the grant, and the remaining half vesting on the one-year anniversary date of the grant, pursuant to a grant under the Plan at an exercise price of $1.16 each. Read SEC document |
| October 01, 2025 Filed Oct 4, 2025 00:00 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantCommon Stock | 2,685,456 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-25-016957 · ownership.xml · nonDerivative · entry 1 Aminov Erez · CIK 0001986112 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,530,156 F1 · security: Represents 2,685,456 restricted shares of common stock, par value $0.0001 of the Issuer issued as compensation for the Issuer's acquisition of SKNY Pharmaceuticals, Inc. F1 · price: Represents 2,685,456 restricted shares of common stock, par value $0.0001 of the Issuer issued as compensation for the Issuer's acquisition of SKNY Pharmaceuticals, Inc. Read SEC document |
| September 18, 2025 Filed Sep 19, 2025 00:00 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantStock Options (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001493152-25-014114 · ownership.xml · derivative · entry 2 Aminov Erez · CIK 0001986112 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-08-17 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on September 15, 2025. F4 · kind: The board of directors of the Company approved to reprice the options from its previous exercise price of $6.50 to $1.38. All of the other terms of the option remain unchanged. F5 · shares: The options were previously issued to the Reporting Person on August 17, 2023, and are now fully vested. F2 · derivative.exercise_date: The board of directors of the Company approved to reprice the options from its previous exercise price of $5.00 to $1.38. All of the other terms of the option remain unchanged. F5 · derivative.underlying_shares: The options were previously issued to the Reporting Person on August 17, 2023, and are now fully vested. Read SEC document |
| September 18, 2025 Filed Sep 19, 2025 00:00 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantStock Options (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001493152-25-014114 · ownership.xml · derivative · entry 1 Aminov Erez · CIK 0001986112 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-04-28 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on September 15, 2025. F2 · kind: The board of directors of the Company approved to reprice the options from its previous exercise price of $5.00 to $1.38. All of the other terms of the option remain unchanged. F3 · shares: The options were previously issued to the Reporting Person on April 28, 2023, and are now fully vested. F2 · derivative.exercise_date: The board of directors of the Company approved to reprice the options from its previous exercise price of $5.00 to $1.38. All of the other terms of the option remain unchanged. F3 · derivative.underlying_shares: The options were previously issued to the Reporting Person on April 28, 2023, and are now fully vested. Read SEC document |
| August 29, 2025 Filed Sep 3, 2025 20:05 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantCommon Stock | 62,500 | $1.37 | $85,625.00 |
DisclosureSEC source: 0001641172-25-026388 · ownership.xml · nonDerivative · entry 1 Aminov Erez · CIK 0001986112 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 844,700 F1 · security: Represents 62,500 RSUs vesting immediately, granted and issued to the Reporting Person from the Issuer's 2022 Omnibus Incentive Plan in connection with the Reporting Person's achievement of certain milestones pursuant to the Reporting Person's Executive Incentive Compensation Plan. Read SEC document |
| May 28, 2025 Filed May 31, 2025 00:00 UTC | Telomir Pharmaceuticals, Inc. TELO · Entity 6962 | GrantRestricted Stock Units (RSUs) · Derivative | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-013148 · ownership.xml · derivative · entry 2 Aminov Erez · CIK 0001986112 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The RSUs were issued to the Reporting Person on May 28, 2025, pursuant to a grant under the Plan. The RSUs are fully vested as of the date of grant. F5 · derivative.expiration_date: Each restricted stock unit represents a right to receive one share of Issuer's common stock. Read SEC document |
| May 28, 2025 Filed May 31, 2025 00:00 UTC | Telomir Pharmaceuticals, Inc. TELO · Entity 6962 | GrantNon-Qualified Options · Derivative | 2,000,000 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001641172-25-013148 · ownership.xml · derivative · entry 1 Aminov Erez · CIK 0001986112 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2035-05-28 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on May 27, 2025. F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on May 28, 2025, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). The stock options are fully vested as of the date of grant. Read SEC document |
| March 26, 2025 Filed Feb 18, 2026 01:30 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantCommon Stock | 62,500 | $1.45 | $90,625.00 |
DisclosureSEC source: 0001493152-26-007226 · ownership.xml · nonDerivative · entry 2 Aminov Erez · CIK 0001986112 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,592,666 F1 · kind: Represents the grant of Issuer's common stock, par value $0.0001 ("Common Stock") that should have been reported on Form 4. F2 · kind: Represents grants of RSUs with underlying shares of Common Stock under the Issuer's 2024 Omnibus Equity Incentive Plan (the "Plan"), for awards granted in accordance with the Issuer's CEO's Long-Term Incentive Plan. The RSUs hereunder vested upon issuance. Read SEC document |
| March 26, 2025 Filed Feb 18, 2026 01:30 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantCommon Stock | 62,500 | $1.45 | $90,625.00 |
DisclosureSEC source: 0001493152-26-007226 · ownership.xml · nonDerivative · entry 1 Aminov Erez · CIK 0001986112 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,530,166 F1 · kind: Represents the grant of Issuer's common stock, par value $0.0001 ("Common Stock") that should have been reported on Form 4. F2 · kind: Represents grants of RSUs with underlying shares of Common Stock under the Issuer's 2024 Omnibus Equity Incentive Plan (the "Plan"), for awards granted in accordance with the Issuer's CEO's Long-Term Incentive Plan. The RSUs hereunder vested upon issuance. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 22:15 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantRestricted Stock Units · Derivative | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-049503 · ownership.xml · derivative · entry 2 Aminov Erez · CIK 0001986112 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2034-12-09 F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F5 · derivative.exercise_date: The RSUs were issued to the Reporting Person on the Grant Date, pursuant to the Plan. Half of the shares subject to the RSU shall vest on the Grant Date and the remaining half of the shares subject to the RSU shall vest six months after the Grant Date. F6 · balance_after: Represents 500,000 RSUs that were issued to the Reporting Person on December 6, 2024 under the Plan. Half of the shares subject to the RSU shall vest on the Grant Date and the remaining half of the shares subject to the RSU shall vest six months after the Grant Date. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 22:15 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantStock Options (right to buy) · Derivative | 2,000,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001493152-24-049503 · ownership.xml · derivative · entry 1 Aminov Erez · CIK 0001986112 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2034-12-09 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on December 6, 2024. F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on December 6, 2024 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). Half of the shares subject to the option shall vest on the Grant Date and the remaining half of the shares subject to the option shall vest six months after the Grant Date. F3 · balance_after: Represents 2,000,000 stock options that were issued to the Reporting Person on December 6, 2024 under the Plan. Half of the shares subject to the option shall vest on the Grant Date and the remaining half of the shares subject to the option shall vest six months after the Grant Date. Read SEC document |
| November 20, 2024 Filed Nov 27, 2024 21:15 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | SaleCommon Stock | 44,590 | $1.27 | $56,629.30 |
DisclosureSEC source: 0001493152-24-047998 · ownership.xml · nonDerivative · entry 2 Aminov Erez · CIK 0001986112 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,061,200 F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b51 Trading Plan adopted by the Reporting Person on 8/20/2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. Read SEC document |
| November 19, 2024 Filed Nov 27, 2024 21:15 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | SaleCommon Stock | 55,410 | $1.39 | $77,019.90 |
DisclosureSEC source: 0001493152-24-047998 · ownership.xml · nonDerivative · entry 1 Aminov Erez · CIK 0001986112 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,105,790 F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b51 Trading Plan adopted by the Reporting Person on 8/20/2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. Read SEC document |
| August 27, 2024 Filed Aug 29, 2024 20:05 UTC | Telomir Pharmaceuticals, Inc. TELO · Entity 6962 | GrantIncentive Stock Options (right to buy) · Derivative | 1,960,170 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0001493152-24-034370 · ownership.xml · derivative · entry 1 Aminov Erez · CIK 0001986112 · Director · CEO & Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,960,170 Underlying: Common Stock · 1,960,170 shares Expires 2034-08-27 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 26, 2024. F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on August 26, 2024, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). Fifty percent of the stock options vested immediately upon issuance and the remaining fifty percent of the stock options are to vest on February 26, 2025. F2 · balance_after: The stock options were issued to the Reporting Person on August 26, 2024, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). Fifty percent of the stock options vested immediately upon issuance and the remaining fifty percent of the stock options are to vest on February 26, 2025. Read SEC document |
| August 19, 2024 Filed Feb 4, 2025 21:05 UTC | Telomir Pharmaceuticals, Inc. TELO · Entity 6962 | SaleCommon Stock | 200 | $6.20 | $1,240.00 |
DisclosureSEC source: 0001493152-25-004853 · ownership.xml · nonDerivative · entry 2 Aminov Erez · CIK 0001986112 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,600 F1 · kind: Represents the sale of common stock that should have been reported on Form 4. Read SEC document |
| August 19, 2024 Filed Feb 4, 2025 21:05 UTC | Telomir Pharmaceuticals, Inc. TELO · Entity 6962 | SaleCommon Stock | 200 | $6.01 | $1,202.00 |
DisclosureSEC source: 0001493152-25-004853 · ownership.xml · nonDerivative · entry 1 Aminov Erez · CIK 0001986112 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,600 F1 · kind: Represents the sale of common stock that should have been reported on Form 4. Read SEC document |
| May 28, 2024 Filed May 30, 2024 22:00 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantIncentive Stock Options (right to buy) · Derivative | 379,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001493152-24-022029 · ownership.xml · derivative · entry 1 Aminov Erez · CIK 0001986112 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 629,000 Underlying: Common Stock · 379,000 shares Expires 2034-05-28 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on May 28, 2024. F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on May 28, 2024, pursuant to a grant under the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). The stock options vested in full and became exercisable immediately upon issuance on the grant date, May 28, 2024. F3 · balance_after: Represents 50,000 stock options that were issued to the Reporting Person on April 28, 2023 that were vested in full and became exercisable on the same date, pursuant to a grant under the Issuer's Plan at an exercise price of $5.00 each, (ii) 150,000 stock options that were issued to the Reporting Person on August 17, 2023, pursuant to a grant under the Issuer's Plan which vested in full on August 17, 2023 at an exercise price of $6.50 each, (iii) 50,000 stock options that were issued to the Reporting Person on August 17, 2023 that vested in full and became exercisable on April 28, 2024, pursuant to a grant under the Issuer's Plan at an exercise price of $6.50 each, and (iv) 379,000 stock options that were issued to the Reporting Person on May 28, 2024 that were vested in full and became exercisable on the same date, pursuant to a grant under the Issuer's Plan at an exercise price of $0.84 each. Read SEC document |
| May 21, 2024 Filed May 22, 2024 21:42 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | PurchaseCommon Stock | 800 | $0.97 | $776.00 |
DisclosureSEC source: 0001493152-24-021069 · ownership.xml · nonDerivative · entry 8 Aminov Erez · CIK 0001986112 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 382,200 F1 · ownership.direct: These securities are directly owned by Mr. Aminov. Read SEC document |
| May 21, 2024 Filed May 22, 2024 21:42 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | PurchaseCommon Stock | 800 | $1.01 | $808.00 |
DisclosureSEC source: 0001493152-24-021069 · ownership.xml · nonDerivative · entry 7 Aminov Erez · CIK 0001986112 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 381,400 F1 · ownership.direct: These securities are directly owned by Mr. Aminov. Read SEC document |
| May 21, 2024 Filed May 22, 2024 21:42 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | PurchaseCommon Stock | 600 | $0.87 | $522.00 |
DisclosureSEC source: 0001493152-24-021069 · ownership.xml · nonDerivative · entry 6 Aminov Erez · CIK 0001986112 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,600 F1 · ownership.direct: These securities are directly owned by Mr. Aminov. Read SEC document |
| May 21, 2024 Filed May 22, 2024 21:42 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | PurchaseCommon Stock | 1,000 | $0.85 | $850.00 |
DisclosureSEC source: 0001493152-24-021069 · ownership.xml · nonDerivative · entry 5 Aminov Erez · CIK 0001986112 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,000 F1 · ownership.direct: These securities are directly owned by Mr. Aminov. Read SEC document |
| May 21, 2024 Filed May 22, 2024 21:42 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | PurchaseCommon Stock | 2,000 | $0.84 | $1,680.00 |
DisclosureSEC source: 0001493152-24-021069 · ownership.xml · nonDerivative · entry 4 Aminov Erez · CIK 0001986112 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 379,000 F1 · ownership.direct: These securities are directly owned by Mr. Aminov. Read SEC document |
| May 21, 2024 Filed May 22, 2024 21:42 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | PurchaseCommon Stock | 500 | $1.02 | $510.00 |
DisclosureSEC source: 0001493152-24-021069 · ownership.xml · nonDerivative · entry 3 Aminov Erez · CIK 0001986112 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 377,000 F1 · ownership.direct: These securities are directly owned by Mr. Aminov. Read SEC document |
| May 21, 2024 Filed May 22, 2024 21:42 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | PurchaseCommon Stock | 1,000 | $1.03 | $1,030.00 |
DisclosureSEC source: 0001493152-24-021069 · ownership.xml · nonDerivative · entry 2 Aminov Erez · CIK 0001986112 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 376,500 F1 · ownership.direct: These securities are directly owned by Mr. Aminov. Read SEC document |
| May 21, 2024 Filed May 22, 2024 21:42 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | PurchaseCommon Stock | 2,000 | $1.00 | $2,000.00 |
DisclosureSEC source: 0001493152-24-021069 · ownership.xml · nonDerivative · entry 1 Aminov Erez · CIK 0001986112 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,500 F1 · ownership.direct: These securities are directly owned by Mr. Aminov. Read SEC document |
| March 26, 2024 Filed Mar 27, 2024 21:53 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantIncentive Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001493152-24-011573 · ownership.xml · derivative · entry 1 Aminov Erez · CIK 0001986112 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 300,000 shares Expires 2034-03-26 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on March 26, 2024. F2 · derivative.exercise_date: The options were granted under the Issuer's 2022 Amended and Restated Omnibus Incentive Plan (the "Plan") whereby 50% of such incentive options, or 150,000 options, will vest on the six month anniversary of the of the grant, or September 26, 2024, and the remaining 50% will vest on the first anniversary of the grant date, March 26, 2025. F3 · balance_after: Represents 50,000 stock options that were issued to the Reporting Person on April 28, 2023 that were vested in full and became exercisable on the same date, pursuant to a grant under the Issuer's Plan at an exercise price of $5.00 each, (ii) 150,000 stock options were issued to the Reporting Person on August 17, 2023, pursuant to a grant under the Issuer's Plan which vested in full on August 17,2023 at an exercise price of $6.50 each and (iii) 50,000 stock options were issued to the Reporting Person on August 17, 2023, pursuant to a grant under the Issuer's Plan which will vest in full on April 28. 2024 at an exercise price of $6.50 each. Read SEC document |
| August 17, 2023 Filed Aug 21, 2023 22:00 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantStock Options · Derivative | 150,000 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001493152-23-029732 · ownership.xml · derivative · entry 1 Aminov Erez · CIK 0001986112 · Director · CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-08-17 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 17, 2023. F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on August 17,2023, pursuant to a grant under the Issuer's 2022 Omnibus Incentive Plan, as amended and restated. The award vests in full on August 17,2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.